ULYSSES NEUROSCIENCE LIMITED

Ulysses Neuroscience Ltd. is a vanguard contract research organisation that bridges pre‑clinical discovery and clinical translation for neuropsychiatric, neurodegenerative and rare neurological disorders. Based in Ireland, with a state‑of‑the‑art Cherrywood laboratory, the company offers a seamless, end‑to‑end platform that moves programmes from target validation straight through to IND‑enabling studies and biomarker‑driven clinical development.

The Preclinical Neuropharmacology division delivers a full suite of CNS drug‑discovery services, including validated behavioural assays, in‑vivo electrophysiology, EEG, and PK/PD profiling across rodent and canine models. Its portfolio covers depression, anxiety, cognition, seizure susceptibility and psychedelic therapeutics, and is supported by HPRA‑accredited facilities in Ireland and AAALAC‑accredited sites in North America. The Translational Medicine division complements this with human‑iPSC‑derived neuronal models, comprehensive biomarker panels (Tau, pTau, GFAP, neurofilament light chain, neuroinflammation and synaptic proteins) and HPRA‑approved biobanking, all housed under one roof.

By integrating these two divisions, Ulysses Neuroscience provides pharmaceutical and biotech partners with a single, patient‑centric hub that accelerates drug discovery across CNS therapeutic areas, from early‑stage research to clinical readiness.